COMMUNIQUÉS West-GlobeNewswire

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
11/12/2024
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH Data Review Meeting [...]
Two Senior MEDIROM Mother Labs Executives Invest in Mother Labs’ Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000)
11/12/2024
TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that two senior executives, Issei Homan, Chief Technology Officer of MEDIROM MOTHER Labs [...]
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
10/12/2024
NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, [...]
Cellectis annonce le tirage de la troisième tranche de 5 millions d’euros dans le cadre du contrat de crédit conclu avec la Banque Européenne d’Investissement (BEI)
10/12/2024
NEW YORK , 10 déc. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS - NASDAQ : CLLS) (la "Société"), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome pour [...]
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
10/12/2024
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
10/12/2024
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance Company continues focus on development of subcutaneous lonigutamab in thyroid eye disease, [...]
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
10/12/2024
TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing [...]
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
10/12/2024
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced the election of Mark S. Davis to its Board of Directors, effective [...]
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
10/12/2024
FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today [...]
Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced
10/12/2024
Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpox Study stopped enrolling patients in all study arms Results affirm [...]
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
10/12/2024
MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of [...]
Theratechnologies reçoit de la FDA la date cible d’approbation de mars 2025 à la licence de produit biologique mise à jour pour la formulation F8 de la tésamoréline
10/12/2024
MONTRÉAL, 10 déc. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur la mise au point et la commercialisation de [...]
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
10/12/2024
WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T [...]
UPDATE - Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting
10/12/2024
– RPT1G synergizes with venetoclax to yield an eightfold reduction in AML leukemia burden – RPT1G increases the efficacy of venetoclax in venetoclax-resistant AML cells by fourfold versus venetoclax alone GAITHERSBURG, [...]
Nutrify Today Introduces a Trio of Innovations to Strengthen NutrifyGenie AI Capabilities
10/12/2024
BANGALORE, India, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nutrify Today unveils a trio of new offerings designed to enhance its flagship AI platform, NutrifyGenie , providing companies with powerful tools to accelerate the [...]
Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m
10/12/2024
CROSSJECT INTENDS TO AMEND THE HEIGHTS CAPITAL MANAGEMENT, INC. (“HEIGHTS”) BONDS CONVERTIBLE INTO NEW SHARES OR REPAYABLE, UNDER CERTAIN CONDITIONS DIJON , FRANCE, December 10, 2024 – 7:15 p.m. (CET) – Crossject (ISIN [...]
Crossject annonce une augmentation de capital et une emission de bons de souscription d’actions reservee à une catégorie d’investisseurs pour un montant total minimum de 7 millions d’euros
10/12/2024
CROSSJECT ENVISAGE DE MODIFIER LES TERMES ET CONDITIONS DES OBLIGATIONS CONVERTIBLES EN ACTIONS NOUVELLES OU REMBOURSABLES SOUSCRITES PAR HEIGHTS CAPITAL MANAGEMENT, INC. (« HEIGHTS »), SOUS CERTAINES CONDITIONS DIJON [...]
CARBIOS announces the initiation of coverage of its stock by STIFEL
10/12/2024
Clermont-Ferrand (France), Tuesday 10 December 2024 (6:00pm CET). CARBIOS , (Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of [...]
CARBIOS annonce l’initiation de couverture de son titre par STIFEL
10/12/2024
Clermont-Ferrand (France), le mardi 10 décembre 2024 (18h00 CET). CARBIOS , (Euronext Growth Paris : ALCRB), pionnière dans le développement et l'industrialisation de technologies biologiques pour réinventer le cycle de [...]

Pages